IDEXX Laboratories, Inc. $IDXX Shares Acquired by Public Employees Retirement Association of Colorado

Public Employees Retirement Association of Colorado increased its position in IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 438.3% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 41,388 shares of the company’s stock after buying an additional 33,700 shares during the quarter. Public Employees Retirement Association of Colorado’s holdings in IDEXX Laboratories were worth $28,000,000 at the end of the most recent reporting period.

Several other institutional investors have also modified their holdings of IDXX. Elyxium Wealth LLC acquired a new stake in shares of IDEXX Laboratories in the fourth quarter valued at $3,666,459,000. Northwestern Mutual Wealth Management Co. lifted its holdings in shares of IDEXX Laboratories by 63,503.9% in the fourth quarter. Northwestern Mutual Wealth Management Co. now owns 1,444,445 shares of the company’s stock valued at $977,210,000 after buying an additional 1,442,174 shares during the period. Norges Bank acquired a new stake in shares of IDEXX Laboratories in the fourth quarter valued at $332,265,000. Arrowstreet Capital Limited Partnership lifted its holdings in shares of IDEXX Laboratories by 197.3% in the fourth quarter. Arrowstreet Capital Limited Partnership now owns 550,368 shares of the company’s stock valued at $372,340,000 after buying an additional 365,274 shares during the period. Finally, JPMorgan Chase & Co. lifted its holdings in shares of IDEXX Laboratories by 60.0% in the third quarter. JPMorgan Chase & Co. now owns 869,930 shares of the company’s stock valued at $555,802,000 after buying an additional 326,348 shares during the period. Institutional investors and hedge funds own 87.84% of the company’s stock.

Wall Street Analyst Weigh In

IDXX has been the subject of several research analyst reports. Wall Street Zen upgraded IDEXX Laboratories from a “hold” rating to a “buy” rating in a report on Saturday. Citigroup initiated coverage on IDEXX Laboratories in a report on Wednesday, April 15th. They issued a “neutral” rating and a $650.00 price objective for the company. Stifel Nicolaus cut their price objective on IDEXX Laboratories from $775.00 to $675.00 and set a “buy” rating for the company in a report on Tuesday, March 31st. UBS Group cut their price objective on IDEXX Laboratories from $730.00 to $640.00 and set a “neutral” rating for the company in a report on Tuesday, April 28th. Finally, Weiss Ratings lowered IDEXX Laboratories from a “hold (c+)” rating to a “hold (c)” rating in a research report on Monday, May 11th. Seven equities research analysts have rated the stock with a Buy rating and four have issued a Hold rating to the company. Based on data from MarketBeat.com, IDEXX Laboratories presently has a consensus rating of “Moderate Buy” and a consensus price target of $751.00.

IDEXX Laboratories Price Performance

NASDAQ:IDXX opened at $560.88 on Monday. The firm has a market capitalization of $44.24 billion, a price-to-earnings ratio of 41.30, a PEG ratio of 3.07 and a beta of 1.56. IDEXX Laboratories, Inc. has a 1-year low of $506.91 and a 1-year high of $769.98. The company has a current ratio of 1.12, a quick ratio of 0.82 and a debt-to-equity ratio of 0.19. The business’s fifty day moving average price is $563.06 and its 200 day moving average price is $626.82.

IDEXX Laboratories (NASDAQ:IDXX) last posted its quarterly earnings results on Tuesday, May 5th. The company reported $3.47 earnings per share for the quarter, beating the consensus estimate of $3.41 by $0.06. The firm had revenue of $1.14 billion for the quarter, compared to analyst estimates of $1.12 billion. IDEXX Laboratories had a return on equity of 70.87% and a net margin of 24.63%.IDEXX Laboratories’s quarterly revenue was up 14.3% on a year-over-year basis. During the same period in the previous year, the firm earned $2.91 earnings per share. IDEXX Laboratories has set its FY 2026 guidance at 14.450-14.900 EPS. On average, sell-side analysts forecast that IDEXX Laboratories, Inc. will post 14.68 earnings per share for the current fiscal year.

IDEXX Laboratories Company Profile

IDEXX Laboratories, Inc (NASDAQ: IDXX) is a global developer, manufacturer and provider of diagnostic products and services primarily for the animal health, water testing and food safety markets. Headquartered in Westbrook, Maine, the company supplies in-clinic diagnostic instruments, consumables, reference laboratory testing and practice-management tools that support veterinarians, livestock and dairy producers, and utilities and food producers worldwide.

IDEXX’s product portfolio includes point-of-care tests and immunoassays designed for rapid diagnosis in veterinary clinics, in-clinic chemistry and hematology analyzers, automated urinalysis systems, and digital diagnostic solutions.